HIV - Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R)
Bavarian Nordic has completed a clinical safety report from a large Phase II study with IMVAMUNE® in HIV infected subjects that confirms the excellent safety profile of IMVAMUNE®. Within the next few days the safety report of this study will be submitted to the FDA and this will trigger a USD 25 million milestone payment under the RFP-3 contract.
More: continued here
Filed under: HIV / AIDS on November 7th, 2008